867000 | KRN7000

α-Galactosyl Ceramide


Powder

Size SKU Packaging Price
1mg 867000P-1mg 867000P-1mg 1 x 1mg $236.25
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

KRN7000

KRN7000

α-Galactosyl Ceramide

KRN7000 is a synthetic analog of α-galactosylceramide and the marine natural product agelasphin. It is a specific ligand for human and mouse NKT cells and remains the best studied ligand of the lipid-binding MHC class I-like protein CD1d. KRN7000 protects against LPS-induced shock and displays potent antitumor activity in various in vivo models.
Hygroscopic
No
Light Sensitive
No
Molecular Formula
C50H99NO9
Percent Composition
C 69.97%, H 11.63%, N 1.63%, O 16.78
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
158021-47-7
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
858.322
Exact Mass
857.732
Synonyms
<p>αGalCer (2S,3S,4R)-1-O-(D-galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol</p>

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PubMed ID: 31495780

Guevara ML, Jilesen Z, Stojdl D, Persano S. Codelivery of mRNA with α-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration. ACS Omega. 2019 Aug 7;4(8):13015-13026. doi: 10.1021/acsomega.9b00489. eCollection 2019 Aug 20.

PubMed ID: 31460428

Pereira CS, Pérez-Cabezas B, Ribeiro H, Maia ML, Cardoso MT, Dias AF, Azevedo O, Ferreira MF, Garcia P, Rodrigues E, Castro-Chaves P, Martins E, Aguiar P, Pineda M, Amraoui Y, Fecarotta S, Leão-Teles E, Deng S, Savage PB, Macedo MF. Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients. Front Immunol. 2019 Jun 4;10:1264. doi: 10.3389/fimmu.2019.01264. eCollection 2019.

PubMed ID: 31214199

Yu KKQ, Wilburn DB, Hackney JA, Darrah PA, Foulds KE, James CA, Smith MT, Jing L, Seder RA, Roederer M, Koelle DM, Swanson WJ, Seshadri C. Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. Immunogenetics. 2019 May 23. doi: 10.1007/s00251-019-01118-9. [Epub ahead of print]

PubMed ID: 31123763

Lu Y, Zhong MC, Qian J, Calderon V, Cruz Tleugabulova M, Mallevaey T, Veillette A. SLAM receptors foster iNKT cell development by reducing TCR signal strength after positive selection. Nat Immunol. 2019 Apr;20(4):447-457. doi: 10.1038/s41590-019-0334-0. Epub 2019 Mar 4.

PubMed ID: 30833791

Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res. 2000 Aug;6(8):3380-7.

PubMed ID: 10955826
Formulation for dissolving KRN7000:
Using pyrogen-free water, a solution is made of sucrose (57 mg/mL), L-histidine (7.5 mg/mL), and Tween 20 (5 mg/mL). The pH is adjusted to 7.2. KRN7000 is dissolved in a 10:1 (vol:vol) mixture of THF and methanol at a concentration of 1 mg/mL. The KRN7000 solution is added dropwise to the aqueous solution with constant stirring (20 µL KRN7000 solution per mL of aqueous solution). The resulting mixture is sonicated in a bath sonicator for 10 min and filter-sterilized.